We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
PrimeCell™ VP of R&D to Discuss Adult Pluripotent Stem Cell Advances
News

PrimeCell™ VP of R&D to Discuss Adult Pluripotent Stem Cell Advances

PrimeCell™ VP of R&D to Discuss Adult Pluripotent Stem Cell Advances
News

PrimeCell™ VP of R&D to Discuss Adult Pluripotent Stem Cell Advances

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "PrimeCell™ VP of R&D to Discuss Adult Pluripotent Stem Cell Advances "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

PrimeCell™ Therapeutics has announced that its Vice President of Research and Development, Francisco Silva, has been invited to participate in a panel discussion hosted by Sen. Rick Santorum (R-PA) to discuss the Alternative Pluripotent Stem Cells Therapies Enhancement Act (S.2754), which would intensify research into alternative methods of deriving pluripotent stem cells.

PrimeCell Therapeutics' platform allows for the reprogramming of adult germ-line stem cells-PrimeCells-the company's pluripotent proprietary cell line capable of transforming into any cell type.

PrimeCell has already been reprogrammed into heart, nerve, bone and cartilage cells and holds promise for expediting the process from research to therapy.

WHO: Francisco J. Silva, Vice President of Research & Development for PrimeCell Therapeutics. 

Silva is a principal contributor to the company's intellectual property portfolio and oversees the development of all therapeutic platforms. 

He is responsible for PrimeCell Therapeutics' current scientific progress and designs, and also implements the company's premier research developments.

WHAT: PrimeCell Therapeutics LLC, a recently formed subsidiary of PrimeGen Biotech LLC, is devoted exclusively to adult stem cell reprogramming. 

The company has introduced its murine model and initial human results for PrimeCell at several global stem cell conferences.

WHEN: 10:00 am Thursday, June 15th, 2006

WHERE: S-120 U.S. Capitol Building

Advertisement